Survodutide CAS 2805997-46-8

Insert the needle at a 45–90° angle into a pinched skin fold.
Inject slowly until full dose is delivered.
Dispose safely of all syringes and vials after use.

Send Inquiry

Survodutide Powder Supplier | High Purity ≥99% | Bulk Orders from Factory

What is Survodutide ?

Survodutide (BI-456906) CAS 2805997-46-8 is an investigational, once-weekly peptide designed to act on two targets at the same time: the GLP-1 receptor (helps curb appetite and slow stomach emptying) and the glucagon receptor (nudges metabolism/energy use). It's being co-developed by Boehringer Ingelheim and Zealand Pharma for weight management (obesity/overweight) and MASH (a form of fatty-liver disease). It's not approved yet.

Survodutide & Fitness:

▼ Headline effects

Weight/fat loss momentum - phase‑2 obesity studies reported approximately 15–19% average body‑weight loss at higher doses by about 46 weeks with dose escalation.
Appetite control - GLP‑1 signaling supports satiety and slower gastric emptying, aiding adherence to a calorie deficit.
Metabolism support - glucagon‑receptor activity may increase energy expenditure; complements appetite effects.
Liver health signal - in MASH phase‑2, higher rates of MASH resolution and fibrosis improvement versus placebo.

Muscle, strength & training

Lean mass: With substantial weight loss, some lean mass reduction is common. Emphasize adequate protein and progressive resistance training.
Performance: No direct performance boost expected. Early GI effects during titration can disrupt hard sessions-plan lighter weeks if needed.

If you train :

Strength training 2–4×/week; add 1–2×/week zone‑2 cardio for capacity.
Protein intake around 1.6–2.2 g/kg/day to help preserve lean mass while cutting.
Pre‑workout fueling: small, easy carbohydrates if nausea is an issue; avoid fasted training if it reduces performance.
Hydration and electrolytes, especially if GI effects occur early.
Use consistent measurement methods to track body composition; expect fat loss to exceed lean loss overall.
Disclaimer: Informational only, not medical advice.

notes: GI side effects (nausea, vomiting, diarrhea) are most common during dose escalation; titration helps reduce them.

Research Use Only

Hot Tags: survodutide cas 2805997-46-8, China survodutide cas 2805997-46-8 manufacturers, suppliers, factory, Cagrilintide Powder fat loss, CAS 3051672 09 1, weight loss collagen peptides, semaglutide peptide oral, orlistat peptide pills, semaglutide and aod 9604